




Version 2.0 by the U.S. National Library of Medicine  
at the National Institutes of Health

Log in | Register

All Databases | Published | Not Published | Protein | Database | Structure | CDD | PMC | Journals | Books

Search PubMed for

☒ Limits ☐ Preview/Index ☐ History ☐ Clipboard ☐ Details

Limits: **Publication Date to 1994**

Display: AbstractPlus Show 20 Sort By Send to

All: 1 Review: 0

1: **Interferon Res.** 1989 Apr;9(2):227-37.

Links

**Antiviral activity of a novel recombinant human interferon-alpha B/D hybrid.**

Gangemi JD, Lazdins J, Dietrich FM, Matter A, Poncioni B, Hochkeppel HK.

Research Laboratories, Pharmaceuticals Division, CIBA-GEIGY Ltd., Basel, Switzerland.

The antiviral potential of a novel cross-species active, recombinant human interferon-alpha B/D hybrid (rHuIFN-alpha B/D), was evaluated for its efficacy in cultured human monocytes and in several murine models of viral disease. When examined in 14-day-old human monocyte cultures, rHuIFN-alpha B/D was highly effective in preventing viral replication and cell destruction caused by herpes simplex virus type 1 (HSV-1/VR3). The effect observed with 100 units of this hybrid IFN was as good or higher than that observed with equivalent amounts of rHuIFN-alpha A or IFN-gamma. In addition, a single dose (5 x 10<sup>7</sup> U/kg) of rHuIFN-alpha B/D administered several hours after intranasal infection with HSV-1/VR3 suppressed pulmonary virus replication and prevented death due to interstitial pneumonia. Similarly, mice infected with a more aggressive strain of HSV-1 (McIntyre) were protected when this IFN preparation was administered at the time of virus infection and 1 day later. The anti-retroviral activity of rHuIFN-alpha B/D was examined in two murine leukemia retroviral models, Rauscher (RMLV) and Friend (FMLV), and a murine model of acquired immunodeficiency (LP-BMS). Treatment of RMLV or FMLV infected mice significantly prolonged mean survival times and the number of long-term FMLV survivors. These therapeutic effects were demonstrated when IFN was administered on the day of virus infection or as late as 3 days following infection. Transient reversal of the immunosuppressive effects induced by LP-BMS infection was observed when rHuIFN-alpha B/D treatment was initiated at the time of virus infection. Moreover, when rHuIFN-alpha B/D was used together with azidothymidine (AZT), the effect of the combination was better than either drug alone.

PMID: 2641210 [PubMed - indexed for MEDLINE]

**Related Links**

- Standard abbreviations for viruses, myxomatosis, a human influenza virus, and a human influenza virus
- Using recombinant human interferon alpha B/D to treat the mother of a child with HIV
- Immunological effects of alpha interferon or combination with human alpha interferon
- Interferon-alpha subunit 3, alpha-2, complex synthesis
- Interferon gamma protects primary macrophages against infection with human

Display: AbstractPlus Show 20 Sort By Send to

Write to the Help Desk  
NCBI | NIH | NLM  
Department of Health & Human Services  
Privacy Statement | Empower of Information Act | Disclaimer